News

November 15th

Merck settles Vioxx suits from New York, Florida

(Reuters) – Merck & Co has reached settlements to resolve lawsuits from the states of New York, Florida and South Carolina alleging the company misled state regulators about the dangers of the painkiller Vioxx, according to court filings.


November 15th

Probiodrug Announces Top-Line Results of the First Clinical Study of PQ912 for Treatment of Alzheimer’s Disease

PQ912 is a glutaminyl cyclase (QC) inhibitor for the treatment of AD and it is the first QC inhibitor to enter clinical development. The Phase 1 trial, conducted in Switzerland, demonstrated that PQ912 is safe and well tolerated after oral dosing. Dose-proportional pharmacokinetics and a strong pharmacokinetic and pharmacodynamic relationship based on QC inhibition were observed in plasma and cerebrospinal fluid. The combined SAD/MAD study involved 100 volunteers in a blinded, placebo controlled randomized trial.


November 15th

Pfizer’s Lipitor survival strategy under attack

Remember Pfizer ($PFE) CEO Ian Read’s (photo) promise that Lipitor co-pay assistance wouldn’t “disadvantage” payers? Apparently, this is why: The company has struck some aggressive deals with pharmacy benefits managers and healthcare plans, trading large discounts for restricted access to Lipitor generics.


November 14th

Myrexis Presents at 2011 EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics Symposium

Myrexis, Inc. MYRX -0.75% , a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today announced that it presented two posters at the 2011 European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on “Molecular Targets and Cancer Therapeutics” in San Francisco, CA.


November 14th

Neuro-biotech startup lands Slater funds

Mnemosyne Pharmaceuticals, a Providence-based neuroscience biotechnology company, has landed a $250,000 investment from the state-backed Slater Technology Fund. Mnemosyne is developing small molecule therapeutics that treat schizophrenia and other cognitive and neuropsychiatric disorders.


November 14th

World Diabetes Day: 552 Million People Could Have Disease by 2030, Report Says

A new report is showing alarming statistics for diabetes — which hits Latinos particularly hard — in the next two decades. The International Diabetes Federation predicts that at least one in 10 adults could have diabetes by 2030, according to its latest statistics.


November 14th

Physical Fitness Associated With Healthier Brain Aging

Physically fit older men and women show fewer age-related changes in their brains, new research shows, buttressing medical evidence that regular exercise can preserve key parts of the brain involved in attention and memory.


November 11th

Otsuka, Lundbeck In Long-Term Development Pact

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S have entered into a long-term agreement for the development and commercialization of as many as five innovative psychiatric and neuroscience products worldwide. The agreement covers early and late stage compounds in development. The two late stage compounds are from Otsuka: aripiprazole depot formulation and OPC-34712. Otsuka has rights to enter into co-development, and co-promotion following approval, of as many as three compounds after Phase IIb trials.


November 11th

Analysts handicap Ranbaxy’s Lipitor copycat

Several analysts have taken a stab at the will-Ranbaxy-launch-generic-Lipitor question. The conclusion? India’s Ranbaxy Labs may just pull it off. But then again, it might not. And even if it does, the penalties Ranbaxy may have to pay to resolve its longstanding regulatory problems could make a Lipitor victory less sweet.


November 11th

Daiichi Sankyo gets access to ArQule cancer drug

Daiichi Sankyo is licensing a new cancer therapy from partner ArQule in a deal that could be worth up to $265 million to the US biotech. The drug in question is ARQ 092 and it is the first compound to emerge from the companies’ November 2008 agreement to collaborate using ArQule technology to generate small molecule kinase inhibitors. It will be studied to identify its utility in targeting the AKT signalling pathway, Daiichi Sankyo noted, which plays a role in regulating cell growth, survival, migration and angiogenesis. Patient enrollment for a Phase I trial will begin in the coming months.